Antifibrotic properties of transarterial oncolytic vsv therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis

Molecular Therapy

Volumn 21, Issue 11, 2013, Pages 2032-2042

  Altomonte, Jennifer ^a   Marozin, Sabrina ^a   De Toni, Enrico N ^b   Rizzani, Antonia ^b   Esposito, Irene ^a,c   Steiger, Katja ^a,c   Feuchtinger, Annette ^c   Hellerbrand, Claus ^d   Schmid, Roland M ^a   Ebert, Oliver ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; THIOACETAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TOXICITY; MALE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN CONTENT; RAT; SAFETY; STAGING; STELLATE CELL; TUMOR CELL DESTRUCTION; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

RATTUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEP G2 CELLS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER NEOPLASMS; MALE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RATS; RATS, INBRED BUF; THIOACETAMIDE; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 84887442307     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.181     Document Type: Article

References (37)

1. Parkin, DM, Bray, F, Ferlay, J and Pisani, P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156.
2. Okuda, H (2007). Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 21: 161-173.
3. Mazzanti, R, Gramantieri, L and Bolondi, L (2008). Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 29: 130-143.
4. Colombo, M (1993). Hepatocellular carcinoma in cirrhotics. Semin Liver Dis 13: 374-383.
5. Lefton, HB, Rosa, A and Cohen, M (2009). Diagnosis and epidemiology of cirrhosis. Med Clin North Am 93: 787-99, vii.
6. Lim, YS and Kim, WR (2008). The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 12: 733-46, vii.
7. Hernandez-Gea, V and Friedman, SL (2011). Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456.
8. Povero, D, Busletta, C, Novo, E, di Bonzo, LV, Cannito, S, Paternostro, C et al. (2010). Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25: 1075-1091.
9. Friedman, SL and Bansal, MB (2006). Reversal of hepatic fibrosis-fact or fantasy? Hepatology 43 (2 Suppl. 1): S82-S88.
10. Kisseleva, T and Brenner, DA (2007). Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 22 (Suppl. 1): S73-S78.
11. Elsharkawy, AM, Oakley, F and Mann, DA (2005). The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10: 927-939.
12. Poynard, T, McHutchison, J, Davis, GL, Esteban-Mur, R, Goodman, Z, Bedossa, P et al. (2000). Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32: 1131-1137.
13. Nowatzky, J, Knorr, A, Hirth-Dietrich, C, Siegling, A, Volk, HD, Limmer, A et al. (2013). Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis. Hepatol Res 43: 535-546.
14. Li, YL, Wu, J, Wei, D, Zhang, DW, Feng, H, Chen, ZN et al. (2009). Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice. Liver Int 29: 593-602.
15. Ebert, O, Shinozaki, K, Huang, TG, Savontaus, MJ, García-Sastre, A and Woo, SL (2003). Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 63: 3605-3611.
16. Shinozaki, K, Ebert, O, Kournioti, C, Tai, YS and Woo, SL (2004). Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 9: 368-376.
17. Ebert, O, Harbaran, S, Shinozaki, K and Woo, SL (2005). Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immunecompetent mice. Cancer Gene Ther 12: 350-358.
18. Kawai, S, Enzan, H, Hayashi, Y, Jin, YL, Guo, LM, Miyazaki, E et al. (2003). Vinculin: a novel marker for quiescent and activated hepatic stellate cells in human and rat livers. Virchows Arch 443: 78-86.
19. Benyon, RC, Iredale, JP, Goddard, S, Winwood, PJ and Arthur, MJ (1996). Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110: 821-831.
20. Takahara, T, Furui, K, Yata, Y, Jin, B, Zhang, LP, Nambu, S et al. (1997). Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 26: 1521-1529.
21. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
22. Kuriyama, S, Yamazaki, M, Mitoro, A, Tsujimoto, T, Kikukawa, M, Tsujinoue, H et al. (1999). Hepatocellular carcinoma in an orthotopic mouse model metastasizes intrahepatically in cirrhotic but not in normal liver. Int J Cancer 80: 471-476.
23. Radaeva, S, Sun, R, Jaruga, B, Nguyen, VT, Tian, Z and Gao, B (2006). Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130: 435-452.
24. Muhanna, N, Abu Tair, L, Doron, S, Amer, J, Azzeh, M, Mahamid, M et al. (2011). Amelioration of hepatic fibrosis by NK cell activation. Gut 60: 90-98.
25. Altomonte, J, Wu, L, Chen, L, Meseck, M, Ebert, O, García-Sastre, A et al. (2008). Exponential enhancement of oncolytic vesicular stomatitis virus potency by vectormediated suppression of inflammatory responses in vivo. Mol Ther 16: 146-153.
26. Altomonte, J, Wu, L, Meseck, M, Chen, L, Ebert, O, Garcia-Sastre, A et al. (2009). Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 16: 266-278.
27. Dooley, S and ten Dijke, P (2012). TGF-ß in progression of liver disease. Cell Tissue Res 347: 245-256.
28. Huang, KW, Huang, YC, Tai, KF, Chen, BH, Lee, PH and Hwang, LH (2008). Dual therapeutic effects of interferon-alpha gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis. Mol Ther 16: 1681-1687.
29. Shinozaki, K, Ebert, O and Woo, SL (2005). Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41: 196-203.
30. Altomonte, J, Braren, R, Schulz, S, Marozin, S, Rummeny, EJ, Schmid, RM et al. (2008). Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 48: 1864-1873.
31. Greenbaum, LE and Wells, RG (2011). The role of stem cells in liver repair and fibrosis. Int J Biochem Cell Biol 43: 222-229.
32. Marozin, S, De Toni, EN, Rizzani, A, Altomonte, J, Junger, A, Schneider, G et al. (2010). Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. PLoS ONE 5: e10988.
33. Birerdinc, A and Younossi, ZM (2010). Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs 15: 535-544.
34. Nicoletti, I, Migliorati, G, Pagliacci, MC, Grignani, F and Riccardi, C (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279.
35. Hartl, I, Schneider, RM, Sun, Y, Medvedovska, J, Chadwick, MP, Russell, SJ et al. (2005). Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther 12: 918-926.
36. Marozin, S, Altomonte, J, Stadler, F, Thasler, WE, Schmid, RM and Ebert, O (2008). Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther 16: 1789-1797.
37. Desmet, VJ, Gerber, M, Hoofnagle, JH, Manns, M and Scheuer, PJ (1994). Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520.